Table 2 Baseline characteristics of large B cell lymphoma treated with CD19 chimeric antigen receptor T cells.
Baseline parameters | N = 60 (%) |
|---|---|
Median Age at Chimeric Antigen Receptor T Cell (range) | 63 (19.5–85.9) years |
Gender (Male:Female) | 42:18 |
Histopathological diagnosis | |
      De novo diffuse large B cell lymphoma | 35 (58.3) |
      Transformed indolent lymphoma | 25 (41.7) |
Stage | |
      Stage 1–2 | 14 (23.3) |
      Stage 3–4 | 38 (63.3) |
      Not available | 8 (13.3) |
ECOG Performance status | |
      0–1 | 44 (73.3) |
      2 | 10 (16.7) |
      3 | 2 (3.3) |
      Not available | 4 (6.7) |
Median number of treatment lines prior to CAR T cells (range) | 3 (2–9) |
Response to prior treatments | |
      Primary refractory disease | 10 (16.7) |
      Relapsed disease | 50 (83.3) |
Presence of bulky disease | |
      Yes | 9 (15.0) |
      No | 45 (75.0) |
      Not available | 6 (10.0) |
History of hematopoietic stem cell transplant prior to CAR T cells | |
      Allogeneic hematopoietic stem cell transplanta | 12 (20.0) |
      Autologous hematopoietic stem cell transplanta | 5 (8.3) |
      No | 44 (73.3) |
Bridging treatment before CAR T cell | |
      High-Intensity systemic therapy | 23 (38.3) |
      Low-Intensity systemic therapyb | 11 (18.3) |
      Radiotherapyb | 5 (8.3) |
      No bridging therapy or systemic corticosteroid | 22 (36.7) |
History of Infection within 30 days before CAR T cell | 24 (40.0) |
Lymphodepletion chemotherapy | |
      Fludarabine cyclophosphamide | 57 (95.0) |
      Bendamustine | 3 (95.0) |
CAR T cell product | |
      Axicabtagene ciloleucel | 43 (71.7) |
      Tisagenlecleucel | 17 (28.3) |
